Chinese Medical Research!丨New Target CAR-T Cell Therapy in R/R MM Patients Sparks Hope and Shapes the Future

🌟Chinese Medical Research!🌟

丨New Target CAR-T Cell Therapy in R/R MM Patients Sparks Hope and Shapes the Future

GPRC5D, Multiple Myeloma

GPRC5D, Multiple Myeloma

🌷”#JournalofClinicalOncology” 🌷

          brings hope for patients with relapsed/refractory #MultipleMyeloma (R/R MM) through a groundbreaking CAR-T cell therapy targeting a “new bull’s eye”.

🌻Led by Professor Xu Kailin’s team

          from Affiliated Hospital of Xuzhou Medical University, this study delved into the efficacy and safety of CAR-T cell therapy targeting GPRC5D in R/R MM patients.


          a member of the G-protein coupled receptor family, showed significantly higher expression on malignant and normal plasma cells in bone marrow compared to peripheral blood cells, laying the groundwork for it to be a prime target for CAR-T cell therapy.
🌺In this study involving 33 R/R MM patients, all received CAR-T cell therapy targeting GPRC5D, with remarkable results! The overall response rate hit 91%(ORR), including a strict complete response rate of 33%. Notably, patients previously treated with BCMA-targeted CAR-T therapy also saw partial or better responses.
🪷Despite these strides in efficacy, safety remains a key concern. The most common adverse events included hematologic toxicities like neutropenia, anemia, and thrombocytopenia, along with cytokine release syndrome and neurotoxicity.
          This study’s findings shine a beacon of hope for R/R MM patients. The GPRC5D-targeted CAR-T cell therapy displays promising clinical efficacy and manageable safety, offering a potential alternative for those progressing after BCMA therapy or developing resistance.
🥀This breakthrough not only expands treatment options for MM patients but also sets a new course for the future development of CAR-T cell therapy.
🌹To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!


#CARTCellTherapy #MultipleMyeloma #ClinicalResearch #HopeForTheFuture #MedicalBreakthroughs #newhope #BCMA #cart #gprc5d #cartcell #celltherapy

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.